Key Highlights

  • Capricor Therapeutics (NASDAQ:CAPR) traded at USD 8.23 in a published screener snapshot, slipping 7.71% in the latest session but climbing 31.93% over one week among small cap weekly gainers.
  • After the company's major amendment, which brought 24 month open label extension data and a narrower upper limb indication, the agency moved the deramiocel decision to November 22, 2026 from August 22, 2026.
  • The HOPE-3 Phase 3 placebo controlled trial enrolled 106 patients, its 12 month results appeared in July 2026, and upper limb open label extension data followed on October 5, 2026.
  • No Revenue was booked, the net loss reached USD 129.4 million or USD 2.23 per share, and Market Value stood at USD 384.3 million at USD 5.88 on July 12, 2026.

A Regulatory Timetable Shift Lifts Capricor Shares

Capricor Therapeutics (NASDAQ:CAPR) develops deramiocel for Duchenne muscular dystrophy, and its shares reached USD 8.23 in the screener snapshot, up 31.93% over one week but off 7.71% in the latest session. Measured from USD 5.88 on July 12, 2026, the price is about 40.0% higher, calculated. Back on June 26, 2026, the company disclosed an FDA advisory committee meeting for July 29, 2026 along with five year HOPE-2 extension data. The original decision date of August 22, 2026 was later moved to November 22, 2026, a Sunday, once the agency classified the company's amendment as major.

Binary Decision Risk and Investor Positioning

No new catalyst for this particular week was pinned down in the pages reviewed. A binary regulatory event explains much of the behavior: as a decision date nears, traders often add exposure on favorable trial news, and prices can swing hard in either direction. The amendment brought 24 month open label extension data, robustness analyses and a narrower upper limb focus, while Lancet publication and October 5, 2026 data at the World Muscle Society congress kept the spotlight on the program. The outcome of the July 29, 2026 advisory committee meeting was not captured in the material reviewed. A shareholder, Kaos Capital, requested a board meeting within 15 Business days on August 21, 2026. A published consensus target of USD 27.00 would sit 228% above USD 8.23, a calculated figure that is not a forecast.

Thin Liquidity and Dilution Risk Without Revenue

With no revenue, valuation rests almost entirely on the regulatory outcome. Market value stood at USD 384.3 million on July 12, 2026, and roughly USD 538 million at USD 8.23 on about 65.4 million shares, calculated. The three month, six month and year to date figures were not visible in the snapshot, though the shares had lost about 77.5% year to date by late August 2026. After a 31.93% weekly advance, a small number of trades can move the price and spreads may be wide. A rejection or delay could reverse the gain, and a fresh offering to finance the launch could dilute holders. The 7.71% drop in the latest session illustrates the volatility.

Where Things Stand

Capricor Therapeutics (NASDAQ:CAPR) gained 31.93% over a week as investors positioned ahead of the November 22, 2026 FDA decision for deramiocel, though no single catalyst for the week was confirmed. In the screener it ranks among small cap weekly gainers, trailing Universal Logistics at 83.75%. At USD 8.23 the shares have recovered from USD 5.88 in July, yet the result is binary and a small cap can reverse quickly.